MA50503A - Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés - Google Patents
Sulfones et sulfoxydes bicycliques et procédés d'utilisation associésInfo
- Publication number
- MA50503A MA50503A MA050503A MA50503A MA50503A MA 50503 A MA50503 A MA 50503A MA 050503 A MA050503 A MA 050503A MA 50503 A MA50503 A MA 50503A MA 50503 A MA50503 A MA 50503A
- Authority
- MA
- Morocco
- Prior art keywords
- sulphones
- sulfoxides
- bicyclic
- related processes
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579392P | 2017-10-31 | 2017-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50503A true MA50503A (fr) | 2020-09-09 |
Family
ID=64051580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050503A MA50503A (fr) | 2017-10-31 | 2018-10-30 | Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11072617B2 (fr) |
| EP (1) | EP3704097B1 (fr) |
| JP (1) | JP2021501183A (fr) |
| KR (1) | KR20200083515A (fr) |
| CN (1) | CN111278809B (fr) |
| AR (1) | AR113811A1 (fr) |
| AU (1) | AU2018360270A1 (fr) |
| BR (1) | BR112020008446A2 (fr) |
| CA (1) | CA3078688A1 (fr) |
| CL (1) | CL2020001062A1 (fr) |
| CO (1) | CO2020003475A2 (fr) |
| CR (1) | CR20200168A (fr) |
| IL (1) | IL273847A (fr) |
| MA (1) | MA50503A (fr) |
| MX (1) | MX2020003451A (fr) |
| PE (1) | PE20211247A1 (fr) |
| PH (1) | PH12020550537A1 (fr) |
| RU (1) | RU2020115915A (fr) |
| SG (1) | SG11202002877RA (fr) |
| TW (1) | TW201922748A (fr) |
| WO (1) | WO2019086494A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| FI3652178T3 (fi) | 2017-07-14 | 2024-03-19 | Hoffmann La Roche | Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| WO2023083847A1 (fr) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines en tant qu'inhibiteurs de ripk1 et leur utilisation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (fr) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipides et composés tensio-actifs en phase aqueuse |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| CA2141216A1 (fr) | 1992-07-27 | 1994-02-03 | Michael J. Micklus | Ciblage de liposomes vers la barriere hemato-encephalique |
| US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| WO1998056376A1 (fr) * | 1997-06-13 | 1998-12-17 | Sugen, Inc. | Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine |
| CA2399791A1 (fr) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1572113B1 (fr) | 2002-08-26 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Compose modulateur de recepteur de calcium et utilisation associee |
| KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
| ES2314418T3 (es) | 2003-05-02 | 2009-03-16 | Elan Pharmaceuticals, Inc. | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. |
| EP1663239A4 (fr) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique |
| EP2083009A1 (fr) * | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Composés tétrahydroimidazopyridine substitués et leur utilisation en tant que médicament |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| KR20140096100A (ko) | 2011-11-03 | 2014-08-04 | 에프. 호프만-라 로슈 아게 | 이환 피페라진 화합물 |
| BR112014026176A2 (pt) | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | dipiridilaminas substituídas e usos das mesmas |
| TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| UA121016C2 (uk) | 2013-05-01 | 2020-03-25 | Ф. Хоффманн-Ля Рош Аг | Бігетероарильні сполуки та їх застосування |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| CN105473554B (zh) | 2013-07-10 | 2019-08-13 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的稠合的哌啶酰胺类 |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| AU2015238541B2 (en) | 2014-03-26 | 2019-09-19 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| AU2015304851A1 (en) | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| WO2016142310A1 (fr) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Inhibiteurs de dlk tricycliques et utilisations associées |
| MX2017016482A (es) | 2015-07-02 | 2018-03-08 | Hoffmann La Roche | Lactamas biciclicas y metodos de uso de las mismas. |
| WO2017096301A1 (fr) | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Inhibiteurs dérivés d'isoxazolidine de protéine kinase 1 interagissant avec un récepteur (ripk 1) |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP6974331B2 (ja) * | 2016-02-05 | 2021-12-01 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 化合物、組成物及び方法 |
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| FI3652178T3 (fi) | 2017-07-14 | 2024-03-19 | Hoffmann La Roche | Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä |
| CN111201229B (zh) | 2017-10-11 | 2024-08-23 | 豪夫迈·罗氏有限公司 | 用作rip1激酶抑制剂的二环化合物 |
-
2018
- 2018-10-30 MA MA050503A patent/MA50503A/fr unknown
- 2018-10-30 PE PE2020000353A patent/PE20211247A1/es unknown
- 2018-10-30 MX MX2020003451A patent/MX2020003451A/es unknown
- 2018-10-30 RU RU2020115915A patent/RU2020115915A/ru unknown
- 2018-10-30 KR KR1020207015138A patent/KR20200083515A/ko not_active Application Discontinuation
- 2018-10-30 AU AU2018360270A patent/AU2018360270A1/en not_active Abandoned
- 2018-10-30 US US16/175,206 patent/US11072617B2/en active Active
- 2018-10-30 CN CN201880070578.0A patent/CN111278809B/zh active Active
- 2018-10-30 SG SG11202002877RA patent/SG11202002877RA/en unknown
- 2018-10-30 EP EP18796020.8A patent/EP3704097B1/fr active Active
- 2018-10-30 TW TW107138469A patent/TW201922748A/zh unknown
- 2018-10-30 JP JP2020524177A patent/JP2021501183A/ja active Pending
- 2018-10-30 CA CA3078688A patent/CA3078688A1/fr active Pending
- 2018-10-30 WO PCT/EP2018/079772 patent/WO2019086494A1/fr active Application Filing
- 2018-10-30 AR ARP180103157A patent/AR113811A1/es unknown
- 2018-10-30 CR CR20200168A patent/CR20200168A/es unknown
- 2018-10-30 BR BR112020008446-8A patent/BR112020008446A2/pt not_active Application Discontinuation
-
2020
- 2020-03-25 CO CONC2020/0003475A patent/CO2020003475A2/es unknown
- 2020-04-06 IL IL273847A patent/IL273847A/en unknown
- 2020-04-20 CL CL2020001062A patent/CL2020001062A1/es unknown
- 2020-04-30 PH PH12020550537A patent/PH12020550537A1/en unknown
-
2021
- 2021-06-06 US US17/340,082 patent/US20230002391A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR113811A1 (es) | 2020-06-10 |
| SG11202002877RA (en) | 2020-04-29 |
| CL2020001062A1 (es) | 2020-08-21 |
| PH12020550537A1 (en) | 2021-03-22 |
| US11072617B2 (en) | 2021-07-27 |
| JP2021501183A (ja) | 2021-01-14 |
| CO2020003475A2 (es) | 2020-04-24 |
| MX2020003451A (es) | 2020-08-03 |
| EP3704097B1 (fr) | 2023-10-25 |
| CN111278809B (zh) | 2024-06-25 |
| EP3704097C0 (fr) | 2023-10-25 |
| PE20211247A1 (es) | 2021-07-13 |
| BR112020008446A2 (pt) | 2020-12-29 |
| RU2020115915A3 (fr) | 2022-05-06 |
| US20190127382A1 (en) | 2019-05-02 |
| WO2019086494A1 (fr) | 2019-05-09 |
| CN111278809A (zh) | 2020-06-12 |
| IL273847A (en) | 2020-05-31 |
| AU2018360270A1 (en) | 2020-03-26 |
| CR20200168A (es) | 2020-07-12 |
| TW201922748A (zh) | 2019-06-16 |
| US20230002391A1 (en) | 2023-01-05 |
| EP3704097A1 (fr) | 2020-09-09 |
| CA3078688A1 (fr) | 2019-05-09 |
| RU2020115915A (ru) | 2021-12-01 |
| KR20200083515A (ko) | 2020-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50503A (fr) | Sulfones et sulfoxydes bicycliques et procédés d'utilisation associés | |
| MA43802A (fr) | Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci | |
| MA44993A (fr) | Polypeptides de fusion cd40l-fc et procédés d'utilisation associés | |
| MA45779A (fr) | Polypeptides immunomdulateurs et compositions et procédés associés | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA44507A (fr) | Récepteurs chimères de flt3 et leurs procédés d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| SG10201707298UA (en) | Dehydrogenation of lpg or ngl and flexible utilization of the olefins thus obtained | |
| EP3359756A4 (fr) | Poutre en treillis à membrures quadruples et plate-forme la contenant | |
| MA40721A (fr) | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA48797A (fr) | Variants de l'endonucléase cblb , compositions et procédés d'utilisation | |
| MA41296A (fr) | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci | |
| MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
| DK3464456T3 (da) | Hængslet komponent omfattende polyethylensammensætning | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| IL267143A (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| MA52988A (fr) | Utilisation anti-inflammatoire du peptide | |
| MA43840A (fr) | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées | |
| ZA201807518B (en) | Benzenesulfonamide compounds and their use as therapeutic agents |